Latest Insider Transactions at Cyclacel Pharmaceuticals, Inc. (CYCC)
This section provides a real-time view of insider transactions for Cyclacel Pharmaceuticals, Inc. (CYCC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cyclacel Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cyclacel Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 29
2024
|
Brian Schwartz Interim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+45.12%
|
-
|
|
Dec 21
2023
|
Spiro George Rombotis President and CEO |
BUY
Open market or private purchase
|
Direct |
6,070
+8.12%
|
$18,210
$3.31 P/Share
|
|
Dec 21
2023
|
Paul Mc Barron Director |
BUY
Open market or private purchase
|
Direct |
1,886
+5.35%
|
$5,658
$3.31 P/Share
|
|
Jun 30
2023
|
Brian Schwartz Interim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+34.32%
|
-
|
|
Jun 30
2023
|
Christopher S Henney Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+35.0%
|
-
|
|
Jun 30
2023
|
Kenneth M. Ferguson Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+32.07%
|
-
|
|
Jun 30
2023
|
Karin L Walker Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+34.32%
|
-
|
|
Jun 30
2023
|
Robert J. Spiegel Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+35.0%
|
-
|
|
Jun 30
2023
|
Sam L Barker Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+34.43%
|
-
|
|
Jan 31
2023
|
Paul Mc Barron Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,200
+49.77%
|
-
|
|
Jan 31
2023
|
Mark Kirschbaum Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,200
+50.0%
|
-
|
|
Jan 31
2023
|
Spiro George Rombotis President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
57,600
+47.92%
|
-
|
|
Jun 14
2022
|
Sam L Barker Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+45.18%
|
-
|
|
Jun 14
2022
|
Christopher S Henney Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+46.51%
|
-
|
|
Jun 14
2022
|
Brian Schwartz Interim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+44.94%
|
-
|
|
Jun 14
2022
|
Lloyd Sems Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+46.51%
|
-
|
|
Jun 14
2022
|
Robert J. Spiegel Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+46.51%
|
-
|
|
Jun 14
2022
|
Karin L Walker Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+44.94%
|
-
|
|
Jun 14
2022
|
Kenneth M. Ferguson Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,733
+50.0%
|
-
|
|
Nov 30
2021
|
Sam L Barker Director |
SELL
Open market or private sale
|
Direct |
12
-0.35%
|
$36
$3.57 P/Share
|
|
Nov 18
2021
|
Spiro George Rombotis President and CEO |
BUY
Open market or private purchase
|
Direct |
4,000
+44.5%
|
$16,000
$4.5 P/Share
|
|
Aug 24
2021
|
Sam L Barker Director |
BUY
Open market or private purchase
|
Direct |
1,000
+22.8%
|
$5,000
$5.0 P/Share
|
|
Jun 15
2021
|
Karin L Walker Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,561
+32.5%
|
-
|
|
Jun 15
2021
|
Brian Schwartz Interim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,561
+32.5%
|
-
|
|
Jun 15
2021
|
Christopher S Henney Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,374
+50.0%
|
-
|
|
Jun 15
2021
|
Robert J. Spiegel Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,374
+50.0%
|
-
|
|
Jun 15
2021
|
Sam L Barker Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,374
+49.87%
|
-
|
|
Jun 15
2021
|
Lloyd Sems Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,374
+50.0%
|
-
|
|
Jun 15
2021
|
Gregory T. Hradsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,374
+50.0%
|
-
|